Ballooning diabetes rates spark investment in research

The dramatic increase in cases of type 2 diabetes has had major public health consequences, and rates are projected to continue to increase. However, the diabetes epidemic has in recent months sparked greater investment in research aimed at finding a cure.

More than 23 million Americans currently have type 2 diabetes and the Centers for Disease Control and Prevention has projected that nearly half of all U.S. adults will have the condition by 2020. This public health crisis has provided researchers and investors with a tremendous opportunity.

For example, a group of venture capital companies recently committed $39.6 million to fund a clinical trial of a diabetes drug being developed by Catabasis Pharmaceuticals of Cambridge, Massachusetts, according to the Wall Street Journal. The drug aims to reduce inflammation, which was recently identified as a major contributor to the development of type 2 diabetes.



Last updated on
First published on
SHOW MAIN MENU
SHOW SUB MENU